They are not the same. All those boosting agents were not mentioned before. Each of the agents must be from a different company. Most importantly, one of the TLR agonists must be TLR4 previously developed by Immune Design which was acquired by Merck for a puny amount of $300m. Had $NWBO published any results on DCVax-L before the acquisition, do you think Merck still was able to acquire the company for $300m?
Yes, there are some old materials in the presentation. You think you really understand those materials? I haven't seen any genuine and seminal understanding about DCVax-L from you. But you did post one laughable piece in which you bragged about statically indeterminate system.
Back to the same material subject, did you see IDO1 was mentioned in the Direct paper? Now tell me why Incyte, an almost Baker Brothers company, is developing IDO1 inhibitor. Does the symbol "I" from the presentation stand for IDO1 inhibitor?
Did you see Treg cells were mentioned in the paper? Tell me which BP owns the inhibitor that can tackle immunosuppresion due to Treg cells. Consider it as a piece of homework. It should be much easier than solving statically indeterminate system. Dude you make me laugh.
Market Data 
Markets 
AI
